Navigation Links
New Treatment Options for Seasonal Affective Disorder, from Harvard Mental Health Letter
Date:11/6/2008

Bright white light therapy has been used to treat seasonal affective disorder (SAD) for more than 20 years. Although it remains a mainstay of treatment, in the past few years researchers have investigated ways to improve and refine light therapy, reports the November 2008 issue of the Harvard Mental Health Letter.

Boston, MA (PRWEB) November 6, 2008 -- Bright white light therapy has been used to treat seasonal affective disorder (SAD) for more than 20 years. Although it remains a mainstay of treatment, in the past few years researchers have investigated ways to improve and refine light therapy, reports the November 2008 issue of the Harvard Mental Health Letter.

Improvements are necessary for three reasons. First, light therapy doesn't work for everyone. Studies have reported that 50% to 80% of patients achieve complete relief and that remission may depend upon carefully individualized timing of light exposure. Second, dosing remains a major question. The recommendation for 30 minutes of daily exposure to 10,000 lux is based on average response to white light. Finally, side effects, while mild for many patients, may be more of a concern for others.

Dr. Michael Miller, editor in chief of the Harvard Mental Health Letter, notes that investigations are now under way to see if changing the timing or type of light therapy might improve response or reduce side effects. Some areas of study:

Better timing. Researchers reported that remission from SAD was twice as likely if light therapy was precisely calibrated to melatonin rhythms--which may vary by several hours from one individual to the next.

Dawn simulation. In this variation, a preset light device turns on before a patient awakens. Light intensity increases gradually over a period of 90 minutes. Although studies so far have been small, they have also been promising.

Blue light. Studies have found that cells in the retina are particularly sensitive to blue light, suggesting that this wavelength may powerfully affect circadian rhythms. Researchers are investigating whether blue light might provide the same benefit as white light but with less exposure time.

For a supplementary video, go online to www.health.harvard.edu/137.

Also in this issue:

  • Treating "first-episode" schizophrenia
  • Positive emotions to resolve disputes
  • The undecided voter

The Harvard Mental Health Letter is available from Harvard Health Publications, the publishing division of Harvard Medical School, for $24 per year. Subscribe at www.health.harvard.edu/mental or by calling 877-649-9457 (toll-free).

Media: Contact Raquel Schott at Raquel_Schott @ hms.harvard.edu for a complimentary copy of the newsletter, or to receive our press releases directly.

Harvard Health Publications
Contact: Raquel Schott
Raquel_Schott @ hms.harvard.edu
617-432-5781

# # #

Read the full story at http://www.prweb.com/releases/Seasonal-Affective/Disorder/prweb1580694.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Webster-Calhoun Cooperative Telephone Association (WCCTA) has sent out notices ... March 14th at 7:00 pm at the Southeast Valley High School Gymnasium located in Gowrie, ... Service" What do you look for in a company when you purchase a ...
(Date:2/28/2017)... ... 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) is proud ... 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has provided the ... Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products and services. ...
(Date:2/28/2017)... Chicago, IL (PRWEB) , ... February 28, 2017 ... ... on Tuesday, March 7, 2017, from 4:30-5:30 p.m. at the 11th Annual RISE ... Stars, quality management, financial compliance, performance analytics, and engagement strategies. , The discussion ...
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata Ananda ... Awakening, is happy to announce her “Spring Rejuvenation in Sedona” personally tailored ... customized retreats offer the winter-weary soul an excellent opportunity to come out of ...
(Date:2/27/2017)... Yorba Linda, Ca (PRWEB) , ... February 27, ... ... Coulter Life Sciences, provides an overview on laser diffraction analysis as a tool ... highlighting its capabilities, significance and potential to obtain improved results and novel scientific ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Pharmaceuticals, Inc. (Nasdaq: IONS ) today reported ... with pro forma operating income of $25.8 million and ... The Company also reported a GAAP loss from operations ... of significant accomplishments for Ionis, culminating in the U.S. ... very broad label. The approval of SPINRAZA is a ...
(Date:2/28/2017)... , Feb. 28, 2017 Prepacked ... and biotechnology industry, food and beverage industry, ... research institutes, and analytical laboratories. Acceptance of ... in the pipelines of pharma companies are ... prepacked chromatography columns market. Increasing research and ...
(Date:2/28/2017)... , Feb. 27, 2017  Titan Pharmaceuticals, ... for the treatment of select chronic diseases utilizing ... announced that the U.S. Food & Drug Administration ... ropinirole implant Investigational New Drug Application (IND) and ... the clinical study pending submission of the requested ...
Breaking Medicine Technology: